Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Novartis (NVS) Stock Price & Analysis

NVS Stock Chart & Stats

$160.79-$0.31(-0.19%)
At close: 4:00 PM EDT
$140$150$1603 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
$160.40 - $164.06
52-Week Range
$122.57 - $170.46
Previous Close
$161.10
Volume
1.83M
Average Volume (3M)
2.03M
Market Cap
$297.25B
Enterprise Value
$311.27B
Total Cash (Recent Filing)
$8.97B
Total Debt (Recent Filing)
$48.31B
Price to Earnings (P/E)
31.2
Beta
0.24
Next Earnings
Feb 03, 2027 (Est.)
EPS Estimate
2.24
Last Dividend Ex-Date
Mar 11, 2026
Dividend Yield
2.95%

Bulls Say, Bears Say

Bulls Say

Growth Portfolio Momentum

Strong growth across multiple priority brands shows that Novartis has several commercially advancing products rather than relying on one medicine. Broad momentum across oncology, immunology, neuroscience and cardiovascular therapies supports durable revenue replacement as older products face erosion.

High-margin Operating Model

The combination of core profit growth, a 41.6% margin and lower SG&A indicates meaningful operating leverage in the business. Continued productivity can help fund research and launches while preserving profitability as Novartis expands its innovation portfolio.

Robust Cash Generation

Large free-cash-flow generation gives Novartis internal funding for clinical development, business development, dividends and repurchases. This financial capacity strengthens the company’s ability to sustain investment in new medicines through normal pipeline volatility.

Bears Say

Higher Financial Leverage

The sharp increase in debt relative to equity reduces balance-sheet flexibility and makes the company more sensitive to earnings volatility and financing costs. Higher leverage can constrain capital allocation if pipeline spending or commercial performance weakens.

Patent And Competitive Erosion

Generic and biosimilar competition can structurally reduce sales and profitability when exclusivity expires, requiring new launches to replace lost revenue. Entresto and Xolair pressure therefore creates an ongoing offset to growth and complicates margin expansion.

Pipeline Execution Setbacks

Multiple late-stage setbacks increase uncertainty around the pipeline’s ability to replenish future growth and reduce the return on prior development investment. The Rhapsido pause also delays a potential expansion, while failed trials can raise future R&D demands.

Novartis News

NVS FAQ

What was Novartis’s price range in the past 12 months?
Novartis lowest stock price was $122.57 and its highest was $170.46 in the past 12 months.
What is Novartis’s market cap?
Novartis’s market cap is $297.25B.
When is Novartis’s upcoming earnings report date?
Novartis’s next earnings report is estimated for Feb 03, 2027 (not yet confirmed), which is in 93 days.
How were Novartis’s earnings last quarter?
Novartis released its earnings results on Oct 27, 2026. The company reported $2.46 earnings per share for the quarter, beating the consensus estimate of $2.271 by $0.189.
Is Novartis overvalued?
According to Wall Street analysts Novartis’s price is currently Overvalued.
Does Novartis pay dividends?
Novartis pays a Annually dividend of $4.74 which represents an annual dividend yield of 2.95%. See more information on Novartis dividends here
What is Novartis’s EPS estimate?
Novartis’s EPS estimate is 2.24.
How many shares outstanding does Novartis have?
Novartis has 2,034,819,500 shares outstanding.
What happened to Novartis’s price movement after its last earnings report?
Novartis reported an EPS of $2.46 in its last earnings report, beating expectations of $2.271. Following the earnings report the stock price went up 1.983%.
Which hedge fund is a major shareholder of Novartis?
Hedge funds hold Novartis shares: the largest hedge-fund position in Novartis is 69,931,220 shares, and hedge funds decreased their holdings by 5.0M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology